Nuvectis Pharma Reports Third-Quarter 2026 Results and Business Highlights

Nuvectis Pharma reported a third-quarter 2026 net loss of $30.1 million, or $1.02 per share, and ended September with $140.7 million in cash. The quarter included a $20.0 million upfront license payment for NXP100 and NXP200 and $1.8 million in NXP900 milestones. The company highlighted progress ac…